e-learning
resources
Munich 2014
Sunday, 07.09.2014
Markers
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Metabolomic signature in COPD. Plasma and lung tissue comparison identify sphingolipids as potential biomakers
V. Pinto-Plata, M. Divo, C. Owen, F. Polverino, M. Laucho, B. Celi (Boston, United States Of America)
Source:
International Congress 2014 – Markers
Session:
Markers
Session type:
Thematic Poster Session
Number:
577
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Pinto-Plata, M. Divo, C. Owen, F. Polverino, M. Laucho, B. Celi (Boston, United States Of America). Metabolomic signature in COPD. Plasma and lung tissue comparison identify sphingolipids as potential biomakers. Eur Respir J 2014; 44: Suppl. 58, 577
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Stable state MR-proadrenomedullin level in COPD patients; a validation study
Source: International Congress 2014 – Comorbidities
Year: 2014
Role of inflammatory biomarkers in COPD
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
What is the best biomarker of COPD stability?
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
Alterations of the soluble proteome of airway epithelial cells in COPD
Source: Annual Congress 2013 –New strategies in epigenomic research to study lung diseases (DNA rearrangements, RNA, methylation, proteosome)
Year: 2013
A multimarker approach to identify atherosclerosis in COPD
Source: International Congress 2014 – Markers
Year: 2014
COPD and lung cancer: Prevalence, infradiagnosis, phenotypes and multidimensional characterization
Source: International Congress 2016 – Epidemiology and specific subgroups in lung cancer
Year: 2016
Gender differences in COPD patients
Source: International Congress 2014 – Clinical presentations
Year: 2014
Evolution of COPD phenotypes in time - Czech multicentre research database of severe COPD
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016
Features of systemic inflammation in patients with stable COPD
Source: International Congress 2014 – COPD: points to ponder
Year: 2014
Plasma metabolomic signature in COPD patients: Associations to proteomic profile and clinical outcomes
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap
Source: Annual Congress 2013 –Is it really asthma?
Year: 2013
What should be part of a comprehensive assessment of COPD?
Source: International Congress 2016 – Best abstracts in COPD management
Year: 2016
Biomarkers in COPD exacerbation, the role of adiponectin
Source: International Congress 2014 – Predictors
Year: 2014
Adrenomedullin optimizes mortality prediction in COPD
Source: International Congress 2014 – COPD exacerbations
Year: 2014
Heterogeneity inside group D COPD patients: About 827 cases
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
Clustering asthma and COPD provides new evidence for both “British” and “Dutch” hypotheses of COPD development
Source: Annual Congress 2013 –Risk factors for COPD and lung function decline
Year: 2013
Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level
Source: International Congress 2014 – COPD markers
Year: 2014
Can red blood cell morphology be an indicator for COPD exacerbations?
Source: International Congress 2014 – Markers
Year: 2014
Increased circulating alveolar epithelial microparticles in COPD patients
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015
The role of COPD in development of osteoporosis
Source: International Congress 2014 – Markers
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept